17577624

Source:http://linkedlifedata.com/resource/pubmed/id/17577624

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0016360, umls-concept:C0024623, umls-concept:C0030705, umls-concept:C0035648, umls-concept:C0205082, umls-concept:C0205179, umls-concept:C0442027, umls-concept:C0879262, umls-concept:C0879626, umls-concept:C0936012
pubmed:issue	2
pubmed:dateCreated	2007-6-19
pubmed:abstractText	S-1 is an oral fluoropyrimidine that promises better and accessible treatment. This article identifies the risk factors for severe adverse events of S-1 from nationwide survey data.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/100886238
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic, http://linkedlifedata.com/resource/pubmed/chemical/Creatinine, http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations, http://linkedlifedata.com/resource/pubmed/chemical/Oxonic Acid, http://linkedlifedata.com/resource/pubmed/chemical/S 1 (combination), http://linkedlifedata.com/resource/pubmed/chemical/Tegafur
pubmed:status	MEDLINE
pubmed:issn	1436-3291
pubmed:author	pubmed-author:FukushimaMasanoriM, pubmed-author:IshiwataRyotaR, pubmed-author:MatsumotoShigemiS, pubmed-author:NagaiYojiY, pubmed-author:TeramukaiSatoshiS, pubmed-author:YamanakaTakeharuT
pubmed:issnType	Print
pubmed:volume	10
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	129-34
pubmed:meshHeading	pubmed-meshheading:17577624-Administration, Oral, pubmed-meshheading:17577624-Adult, pubmed-meshheading:17577624-Aged, pubmed-meshheading:17577624-Aged, 80 and over, pubmed-meshheading:17577624-Antimetabolites, Antineoplastic, pubmed-meshheading:17577624-Creatinine, pubmed-meshheading:17577624-Drug Combinations, pubmed-meshheading:17577624-Female, pubmed-meshheading:17577624-Health Surveys, pubmed-meshheading:17577624-Humans, pubmed-meshheading:17577624-Japan, pubmed-meshheading:17577624-Liver Neoplasms, pubmed-meshheading:17577624-Male, pubmed-meshheading:17577624-Middle Aged, pubmed-meshheading:17577624-Neoplasm, Residual, pubmed-meshheading:17577624-Neoplasm Recurrence, Local, pubmed-meshheading:17577624-Neutrophils, pubmed-meshheading:17577624-Oxonic Acid, pubmed-meshheading:17577624-Platelet Count, pubmed-meshheading:17577624-Product Surveillance, Postmarketing, pubmed-meshheading:17577624-Prospective Studies, pubmed-meshheading:17577624-Risk Factors, pubmed-meshheading:17577624-Stomach Neoplasms, pubmed-meshheading:17577624-Survival Rate, pubmed-meshheading:17577624-Tegafur
pubmed:year	2007
pubmed:articleTitle	Analysis of risk factors for severe adverse effects of oral 5-fluorouracil S-1 in patients with advanced gastric cancer.
pubmed:affiliation	Cancer Biostatics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, 3-1-1 Notame, Fukuoka, Japan.
pubmed:publicationType	Journal Article